BOLT
4:05 PM
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182
boltbio.com